JPRN-UMIN000000941已完成未知
Short Treatment with the Angiotensin Receptor Blocker Candesartan Surveyed by Telemedicine - STAR CAST Study
Department of Internal Medicine, School of Medicine, Keio University0 个研究点目标入组 220 人开始时间: 2008年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 59years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients satisfying any one of the following criteria will be excluded from the study: 1.Secondary hypertension 2.Diabetes mellitus (HbA1c values of 6.5% or greater) 3.Renal dysfunction (serum creatinine values of 2 mg/dl or greater) 4.Patients with a history of cardiovascular disease (stroke, transient ischemic attack, coronary heart disease, heart failure) 5.Patients with severe liver dysfunction 6.Patients with malignancies 7.Pregnant patients, or patients intending to be pregnant 8.Other patients judged to be inappropriate by the attending physician
研究者
相似试验
招募中
不适用
Angiotensin receptor-neprilysin inhibitor in patients with acute myocardial infarction and heart failureAcute myocardial infarctionJPRN-UMIN000046004Chiba University Hospital1,000
招募中
1 期
Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU START-or-NOT trial”.A prospective, randomized, double blinded, multicenter studyEUCTR2020-000414-16-FRAPHP500
已完成
3 期
Controlled evaluation of Angiotensin Receptor Blockers for COVID-19Respiratory DiseaseCTRI/2020/07/026831George Institute for Global Health India778
已完成
不适用
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cancer Risk: A systematic review and network meta-analysisHypertension, Coronary artery disease, Heart failure, Chronic kidney disease, Atrial fibrillation, High risk vascular disease, Cerebrovascular accident, Diabetes mellitus, High normal blood pressure, Pre-hypertensionJPRN-UMIN000048395Yokohama City University Graduate School of Medicine
已完成
4 期
Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure LoweringHypertensionJPRN-UMIN000002531Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30